181 related articles for article (PubMed ID: 16272456)
1. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
Kris MG
Oncologist; 2005 Oct; 10 Suppl 2():23-9. PubMed ID: 16272456
[TBL] [Abstract][Full Text] [Related]
2. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Siegel-Lakhai WS; Beijnen JH; Schellens JH
Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
[TBL] [Abstract][Full Text] [Related]
3. FDA drug approval summary: erlotinib (Tarceva) tablets.
Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
[TBL] [Abstract][Full Text] [Related]
4. Gene-expression profiling and the future of adjuvant therapy.
van de Vijver M
Oncologist; 2005 Oct; 10 Suppl 2():30-4. PubMed ID: 16272457
[TBL] [Abstract][Full Text] [Related]
5. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
Eniu A; Palmieri FM; Perez EA
Oncologist; 2005 Oct; 10(9):665-85. PubMed ID: 16249346
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
Crawford J
Semin Oncol; 1994 Oct; 21(5 Suppl 10):85-8. PubMed ID: 7526468
[TBL] [Abstract][Full Text] [Related]
8. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
Bunn PA
Semin Oncol; 1994 Jun; 21(3 Suppl 6):49-59. PubMed ID: 8052874
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Herbst RS; Sandler A
Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
[TBL] [Abstract][Full Text] [Related]
11. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
12. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
Cohen MH; Johnson JR; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005; 10(6):363-8. PubMed ID: 15967829
[TBL] [Abstract][Full Text] [Related]
13. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.
Splinter TA
Semin Oncol; 1996 Dec; 23(6 Suppl 16):59-61. PubMed ID: 9007124
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
16. Current management of unresectable non-small cell lung cancer.
Livingston RB
Semin Oncol; 1994 Oct; 21(5 Suppl 10):4-11; discussion 11-3. PubMed ID: 7973768
[TBL] [Abstract][Full Text] [Related]
17. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
Belani CP
Semin Oncol; 1999 Feb; 26(1 Suppl 2):44-54. PubMed ID: 10190783
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
20. Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer.
Carney DN
Semin Oncol; 1995 Aug; 22(4 Suppl 9):58-62. PubMed ID: 7644930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
